EGFR and non-small cell lung carcinoma: HS-10296 is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR. An open-label, multicenter, phase I/II trial of HS-10296 with dose escalation, dose expansion, and extension cohorts in locally advanced or metastatic NSCLC patients who have progressed following prior therapy with an EGFR TKI agent is currently recruiting participants (NCT02981108).